We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Clinical Trial Medical-Image Collect-and-Hold System Centralizes Imaging Data

By LabMedica International staff writers
Posted on 20 Aug 2009
A new image management solution has been designed to collect and hold medical images in clinical trials, called iMAS (image management archive system). More...
The iMAS is a cost-effective option for clinical trial sponsors to centralize the collection of the large imaging data sets frequently utilized in clinical trials, while giving them accessibility and secure storage, with minimal investment.

The system was developed by M2S, Inc. (West Lebanon, NH, USA), a global provider of image management services for biopharmaceutical and medical device clinical trials. M2S offers cost-effective medical image management solution for clinical trial sponsors.

"Clinical trial sponsors are facing extraordinary cost pressures in the current economy,” said Wes Chapman, CEO of M2S. "With less time needed for setup, decreased trial complexity, and reduced documentation requirements, an M2S iMAS trial is typically only 20% of the cost of a full clinical trial. This option gives trial sponsors the control and flexibility to adjust a trial and add a blinded radiological review at any point, while simultaneously containing costs.”

While many clinical trials continue to incorporate imaging data for surrogate endpoints, it is not always clear whether image data review and submission will be necessary. However, potentially valuable and expensive imaging data can and probably should still be collected. Sponsors may want to consider using those images for a later submission, subsequent trials or for patient registries, and the risk, cost, and effort of retrospectively collecting images can exceed that of prospective medical image collection.

M2S will customize the iMAS product based on service levels needed for a particular clinical trial--including consultation, project management, and query management. Real-time, web-based reports allow sponsors to see both the status of data gathered as well as access the data anytime, anywhere.

M2S provides medical image data management services across the healthcare continuum based on best-in-class technology and continuous quality improvement processes. M2S clinical trial image-management services include protocol development, electronic image collection, independent review, archive, and real-time web-based data access. M2S clinical data registries provide long-term evaluation of treatment outcomes, benefits, and cost.

Related Links:
M2S


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Automatic CLIA Analyzer
Shine i6000
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.